Summary

for people ages 2-35 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).

Official Title

A Two-Part Study of ZX008 in Children and Adults With Lennox-Gastaut Syndrome (LGS); Part 1: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults With LGS, Followed by Part 2: An Open-Label Extension Trial to Assess Long-Term Safety of ZX008 in Children and Adults With LGS

Keywords

Lennox Gastaut Syndrome LGS Syndrome Pharmaceutical Solutions Fenfluramine ZX008 02 and 0.8 mg/kg/day ZX008 0.2 and 0.8 mg/kg/day Open-Label

Eligibility

For people ages 2-35

Key Inclusion Criteria:

  • Male or non-pregnant, non-lactating female, age 2 to 35 years, inclusive as of the day of the Screening Visit.
  • Clinical diagnosis of Lennox-Gastaut syndrome, where seizures that result in drops are not completely controlled by current antiepileptic treatments.
  • Onset of seizures at 11 years of age or younger.
  • Abnormal cognitive development.
  • Must be receiving at least 1 concomitant AED and up to 4 concomitant anti-epileptic treatments.

Key Exclusion Criteria:

  • Etiology of seizures is a degenerative neurological disease.
  • History of hemiclonic seizures in the first year of life.
  • Subject only has drop seizures in clusters, where individual seizures cannot be counted reliably.
  • Pulmonary arterial hypertension.
  • Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke.
  • Receiving concomitant therapy with: centrally-acting anorectic agents;monoamineoxidase inhibitors; any centrally-acting compound with clinically appreciable amount of serotonin agonist or antagonist properties, including serotonin reuptake inhibition; atomoxetine, or other centrally-acting noradrenergic agonist;cyproheptadine.
  • Taking felbamate for less than 1 year prior to screening and/or does not have stable liver function and hematology laboratory tests, and/or the dose has not been stable for at least 60 days prior to the Screening Visit.
  • Currently receiving an investigational product.
  • Institutionalized in a general nursing home (ie, in a facility that does not specialize in epilepsy care).
  • A clinically significant condition, or has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to the Screening Visit, other than epilepsy, that would negatively impact study participation, collection of study data,or pose a risk to the subject.

Locations

  • University of California San Francisco accepting new patients
    San Francisco California 94143 United States
  • University of Utah accepting new patients
    Salt Lake City Utah 84108 United States
  • Oregon Health & Science University accepting new patients
    Portland Oregon 97239 United States
  • Center for Neurosciences accepting new patients
    Tucson Arizona 85718 United States
  • MultiCare Institute for Research & Innovation accepting new patients
    Tacoma Washington 98405 United States
  • Seattle Children's Hospital not yet accepting patients
    Seattle Washington 98105 United States
  • British Columbia Children's Hospital accepting new patients
    Vancouver British Columbia 6H 3N1 Canada
  • The Children's Hospital Colorado accepting new patients
    Aurora Colorado 80045 United States
  • Ann & Robert Lurie Children's Hospital of Chicago accepting new patients
    Chicago Illinois 80045 United States
  • Cook's Children's Medical Center accepting new patients
    Fort Worth Texas 76104 United States
  • Minnesota Epilepsy Group, PA accepting new patients
    Saint Paul Minnesota 55102 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
ID
NCT03355209
Phase
Phase 3
Study Type
Interventional
Last Updated
July 13, 2018